Dexmedetomidine, an alpha-2 adrenoceptors agonist, provides a neuroprotective effect for dopaminergic neurons in the substantia nigra and attenuates glucose imbalance in the 6-hydroxydopamine animal model of Parkinson’s disease
- 13 May 2024
- journal article
- research article
- Published by Taylor & Francis in Neurological Research
- Vol. 46 (8) , 763-771
Abstract
IntroductionStudies have shown that dexmedetomidine (DEX, an a2-adrenoceptors agonist) provides a neuroprotective effect and influences blood glucose levels. Here, we evaluated the effect of prolonged treatment with low doses of DEX on the survival rate of dopaminergic (DAergic) neurons in the substantia nigra and also serum glucose levels in 6-hydroxydopamine (6-OHDA) - induced Parkinson's disease (PD) in the rat.Material and MethodsThe neurotoxin of 6-OHDA was injected into the medial forebrain bundle by stereotaxic surgery. DEX (25 and 50 mu g/kg, i.p) and yohimbine, an a2-adrenoceptor antagonist (1 mg/kg, i.p) were administered before the surgery to the 13 weeks afterward. Apomorphine-induced rotational tests and blood sampling were carried out before the surgery and multiple weeks after that. Thirteen weeks after the surgery, the rats' brain was transcardially perfused to assess the survival rate of DAergic neurons using the tyrosine hydroxylase (TH) immunohistochemistry.ResultsDEX remarkably attenuated the severity of rotational behavior and reversed the progress of the PD. It also increased the number of TH-labeled neurons by up to 60%. The serum glucose levels in 6-OHDA-received rats did not change in the third and seventh weeks after the surgery but decreased significantly in the thirteenth week. Treatment with DEX prevented this decrement in glucose levels. On the other hand, Treatment with yohimbine did not affect PD symptoms and glucose levels.ConclusionOur data indicate that DEX through neuroprotective activity attenuates the severity of 6-OHDA-induced PD in rats. DEX might also prevent hypoglycemia during the progress of the PD.Keywords
Funding Information
- Qazvin University of Medical Sciences (IR.QUMS.AEC.1401.003)
This publication has 44 references indexed in Scilit:
- Dexmedetomidine attenuates motor deficits via restoring the function of neurons in the nigrostriatal circuit in Parkinson's disease model miceEuropean Journal of Pharmacology, 2022
- Dexmedetomidine attenuates sepsis-associated inflammation and encephalopathy via central α2A adrenoceptorBrain, Behavior, and Immunity, 2020
- Interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-α levels in CSF and serum in relation to the clinical diversity of Parkinson’s diseaseCellular Immunology, 2018
- Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson DiseaseJAMA Neurology, 2017
- Dexmedetomidine Inhibits Tumor Necrosis Factor-Alpha and Interleukin 6 in Lipopolysaccharide-Stimulated Astrocytes by Suppression of c-Jun N-Terminal KinasesInflammation, 2014
- Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in miceBehavioural Brain Research, 2005
- Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's diseaseJournal of Neuroscience Methods, 2005
- Dexmedetomidine produces its neuroprotective effect via the α2A-adrenoceptor subtypeEuropean Journal of Pharmacology, 2004
- Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned ratMolecular Brain Research, 1996
- Interleukin‐1 stimulates glucose transport in rat adipose cellsFEBS Letters, 1990